Sachetelli et al., 1999 - Google Patents
Evaluation of the pulmonary and systemic immunogenicity of fluidosomes, a fluid liposomal–tobramycin formulation for the treatment of chronic infections in lungsSachetelli et al., 1999
View PDF- Document ID
- 7102763911285131599
- Author
- Sachetelli S
- Beaulac C
- Riffon R
- Lagacé J
- Publication year
- Publication venue
- Biochimica et Biophysica Acta (BBA)-General Subjects
External Links
Snippet
In previous studies, we have developed a fluid bactericidal liposomal formulation containing tobramycin, called Fluidosomes, which has been shown to be highly bactericidal both in in vitro and in in vivo studies against Pseudomonas aeruginosa and other related and …
- 239000000203 mixture 0 title abstract description 11
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Frezard | Liposomes: from biophysics to the design of peptide vaccines | |
| Paul et al. | Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes | |
| US4053585A (en) | Immunological preparations | |
| US6004534A (en) | Targeted polymerized liposomes for improved drug delivery | |
| US6060082A (en) | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery | |
| US4196191A (en) | Biological preparations | |
| JP2502234B2 (en) | Liposome-containing vaccine composition | |
| Li et al. | Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo | |
| JPH11512712A (en) | Emulsions and micelle formulations for delivering biologically active substances to cells | |
| Shilpa et al. | Niosomes as vesicular carriers for delivery of proteins and biologicals | |
| US4148876A (en) | Biological preparations | |
| US9750692B2 (en) | Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant | |
| AU2005259685B2 (en) | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids | |
| Sachetelli et al. | Evaluation of the pulmonary and systemic immunogenicity of fluidosomes, a fluid liposomal–tobramycin formulation for the treatment of chronic infections in lungs | |
| CA1079634A (en) | Antigens bound to exterior surface of microvesicles | |
| Williams et al. | Interleukin‐1β (IL‐1β) inhibition: a possible mechanism for the anti‐inflammatory potency of liposomally conjugated methotrexate formulations in arthritis | |
| EP2514410B1 (en) | Liposome composition, preparation method thereof, and usage of the composition as pneumonia vaccine | |
| Van Rooijen et al. | Immunoadjuvant properties of liposomes | |
| Kimoto | Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant | |
| Patel | Influence of lipid composition on opsonophagocytosis of liposomes | |
| US4661346A (en) | Immunological compositions including a peptide and osmium or ruthenium tetroxide | |
| Mirchamsy et al. | Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections | |
| US7381421B2 (en) | Liposomes | |
| García‐Santana et al. | Biodistribution of liposome‐entrapped human gamma‐globulin | |
| CA2761917C (en) | Method for detoxification of lipopolysaccharide (lps) or of lipid a of gram-negative bacteria |